ECSP19000185A - Método para producir derivado de difenilmetano - Google Patents
Método para producir derivado de difenilmetanoInfo
- Publication number
- ECSP19000185A ECSP19000185A ECSENADI2019185A ECDI201900185A ECSP19000185A EC SP19000185 A ECSP19000185 A EC SP19000185A EC SENADI2019185 A ECSENADI2019185 A EC SENADI2019185A EC DI201900185 A ECDI201900185 A EC DI201900185A EC SP19000185 A ECSP19000185 A EC SP19000185A
- Authority
- EC
- Ecuador
- Prior art keywords
- diphenylmethane derivative
- synthesis route
- synthesis
- linear
- sglt
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 title abstract 2
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 2
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000001308 synthesis method Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un método mejorado para producir un derivado de difenilmetano que es eficaz como un inhibidor del cotransportador de glucosa dependiente de sodio (SGLT), el método siendo realizado por medio de un método de síntesis convergente en el que cada grupo principal es sintetizado por separado y luego acoplado. Como tal, en comparación con un método de síntesis lineal descrito en documentos existentes, la vía de síntesis es compacta y el rendimiento puede aumentarse, y los factores de riesgo inherentes a la vía de síntesis lineal pueden reducirse. Además, la forma cristalina del compuesto producido de conformidad con el método tiene excelentes características fisicoquímicas y, por lo tanto, puede utilizarse eficazmente en campos tales como la fabricación de productos farmacéuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160075910 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19000185A true ECSP19000185A (es) | 2019-01-31 |
Family
ID=60664449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI2019185A ECSP19000185A (es) | 2016-06-17 | 2019-01-04 | Método para producir derivado de difenilmetano |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10640496B2 (es) |
| EP (2) | EP3473621B1 (es) |
| JP (4) | JP6763978B2 (es) |
| KR (2) | KR102233229B1 (es) |
| CN (2) | CN113651803B (es) |
| AU (1) | AU2017285813B2 (es) |
| CA (2) | CA3081033C (es) |
| CL (1) | CL2018003645A1 (es) |
| CO (1) | CO2018014018A2 (es) |
| DK (2) | DK3473621T3 (es) |
| DO (1) | DOP2018000287A (es) |
| EC (1) | ECSP19000185A (es) |
| ES (2) | ES2898336T3 (es) |
| HR (1) | HRP20211670T8 (es) |
| HU (1) | HUE056428T2 (es) |
| MA (2) | MA44545B2 (es) |
| MX (2) | MX385640B (es) |
| MY (1) | MY203941A (es) |
| NZ (1) | NZ749398A (es) |
| PE (2) | PE20240590A1 (es) |
| PH (1) | PH12018550206A1 (es) |
| PL (2) | PL3473621T3 (es) |
| PT (2) | PT3473621T (es) |
| RS (1) | RS62550B1 (es) |
| SA (2) | SA521422474B1 (es) |
| SG (2) | SG11201811154QA (es) |
| SI (1) | SI3663292T1 (es) |
| TN (1) | TN2018000437A1 (es) |
| WO (1) | WO2017217792A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011054773A1 (de) | 2011-10-25 | 2013-04-25 | Vb Autobatterie Gmbh & Co. Kgaa | Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols |
| ES2980368T3 (es) * | 2018-08-13 | 2024-10-01 | Daewoong Pharmaceutical Co Ltd | Método para producir un intermediario útil para la síntesis de inhibidor de SGLT |
| CN112341416A (zh) * | 2019-08-09 | 2021-02-09 | 天津津艺医药科技发展有限责任公司 | 一种制备苯并含氧脂杂环衍生物的方法 |
| EP4112612B1 (en) | 2020-02-27 | 2025-10-22 | Daewoong Pharmaceutical Co., Ltd. | Intermediate useful for synthesis of sglt inhibitor and method for preparing sglt inhibitor using same |
| CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
| US12448360B2 (en) * | 2020-09-10 | 2025-10-21 | Daewoong Pharmaceutical Co., Ltd. | Synthesis method for preparing SGLT inhibitor intermediate |
| CN113200860B (zh) * | 2021-04-29 | 2024-07-30 | 爱斯特（成都）生物制药股份有限公司 | 一种sglt2抑制剂中间体的制备方法 |
| KR20230046784A (ko) * | 2021-09-30 | 2023-04-06 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 약학 조성물 |
| CN113801010A (zh) * | 2021-11-18 | 2021-12-17 | 山东诚创蓝海医药科技有限公司 | 一种5-溴-2-氯苯甲酸的制备方法 |
| CN113912487B (zh) * | 2021-11-23 | 2024-05-28 | 山东研峰新材料科技有限公司 | 一种2,5-双卤代苯甲酸的合成方法 |
| KR20230110001A (ko) * | 2022-01-14 | 2023-07-21 | 주식회사 대웅제약 | Ssglt 저해제의 합성에 유용한 중간체의 제조 방법 |
| KR20240044194A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 공결정 |
| KR20240044190A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 결정형 및 이의 제조방법 |
| JP2025532992A (ja) | 2022-09-29 | 2025-10-03 | デーウン ファーマシューティカル カンパニー リミテッド | エナボグリフロジンを含む心血管老化疾患の予防又は治療用薬学組成物｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｎｇ ｏｒ ｔｒｅａｔｉｎｇ ｃａｒｄｉｏｖａｓｃｕｌａｒ ａｇｉｎｇ ｄｉｓｅａｓｅｓ ｃｏｎｔａｉｎｉｎｇ ｅｎａｖｏｇｌｉｆｌｏｚｉｎ｝ |
| MA71282A1 (fr) | 2022-10-05 | 2025-12-31 | Daewoong Pharmaceutical Co., Ltd. | Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine |
| EP4631498A1 (en) | 2022-12-21 | 2025-10-15 | Daewoong Therapeutics Inc. | Eye drop-type pharmaceutical composition containing envogliflozin |
| KR20240107660A (ko) | 2022-12-30 | 2024-07-09 | 주식회사 대웅제약 | 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물 |
| KR102837941B1 (ko) * | 2024-11-13 | 2025-07-25 | 대웅바이오(주) | Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
| KR102837948B1 (ko) * | 2024-11-13 | 2025-07-25 | 대웅바이오(주) | 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
| KR102853437B1 (ko) * | 2024-11-13 | 2025-09-04 | 대웅바이오(주) | 연속반응 공정을 이용한 이나보글리플로진 합성방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966907A (en) * | 1988-08-12 | 1990-10-30 | Merck & Co., Inc. | 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis |
| CN103214471B (zh) * | 2003-08-01 | 2018-02-06 | 田边三菱制药株式会社 | 具有钠依赖型葡萄糖转运体抑制活性的化合物的制备方法 |
| ATE530558T1 (de) | 2007-07-26 | 2011-11-15 | Lexicon Pharmaceuticals Inc | Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern |
| MX2011001062A (es) * | 2008-07-30 | 2011-03-24 | Ferrer Int | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno. |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2012041898A1 (en) * | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
| TR201903445T4 (tr) * | 2011-06-01 | 2019-03-21 | Green Cross Corp | Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇ |
| US9340521B2 (en) * | 2013-03-18 | 2016-05-17 | Green Cross Corporation | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-06-15 US US16/310,005 patent/US10640496B2/en active Active
- 2017-06-15 SI SI201730944T patent/SI3663292T1/sl unknown
- 2017-06-15 PE PE2023002240A patent/PE20240590A1/es unknown
- 2017-06-15 PT PT17813615T patent/PT3473621T/pt unknown
- 2017-06-15 EP EP17813615.6A patent/EP3473621B1/en active Active
- 2017-06-15 KR KR1020170075799A patent/KR102233229B1/ko active Active
- 2017-06-15 SG SG11201811154QA patent/SG11201811154QA/en unknown
- 2017-06-15 TN TNP/2018/000437A patent/TN2018000437A1/en unknown
- 2017-06-15 RS RS20211297A patent/RS62550B1/sr unknown
- 2017-06-15 WO PCT/KR2017/006271 patent/WO2017217792A1/ko not_active Ceased
- 2017-06-15 NZ NZ749398A patent/NZ749398A/en unknown
- 2017-06-15 DK DK17813615.6T patent/DK3473621T3/da active
- 2017-06-15 MX MX2018015647A patent/MX385640B/es unknown
- 2017-06-15 CA CA3081033A patent/CA3081033C/en active Active
- 2017-06-15 PT PT201529591T patent/PT3663292T/pt unknown
- 2017-06-15 HU HUE20152959A patent/HUE056428T2/hu unknown
- 2017-06-15 MX MX2021008988A patent/MX392177B/es unknown
- 2017-06-15 ES ES20152959T patent/ES2898336T3/es active Active
- 2017-06-15 AU AU2017285813A patent/AU2017285813B2/en active Active
- 2017-06-15 PE PE2018003162A patent/PE20190467A1/es unknown
- 2017-06-15 JP JP2018565754A patent/JP6763978B2/ja active Active
- 2017-06-15 PL PL17813615T patent/PL3473621T3/pl unknown
- 2017-06-15 DK DK20152959.1T patent/DK3663292T3/da active
- 2017-06-15 PL PL20152959T patent/PL3663292T3/pl unknown
- 2017-06-15 CN CN202110860586.9A patent/CN113651803B/zh active Active
- 2017-06-15 CN CN201780036968.1A patent/CN109311861B/zh active Active
- 2017-06-15 MY MYPI2018002498A patent/MY203941A/en unknown
- 2017-06-15 MA MA44545A patent/MA44545B2/fr unknown
- 2017-06-15 EP EP20152959.1A patent/EP3663292B1/en active Active
- 2017-06-15 CA CA3026756A patent/CA3026756C/en active Active
- 2017-06-15 HR HRP20211670TT patent/HRP20211670T8/hr unknown
- 2017-06-15 SG SG10201911782RA patent/SG10201911782RA/en unknown
- 2017-06-15 MA MA50774A patent/MA50774B1/fr unknown
- 2017-06-15 ES ES17813615T patent/ES2891825T3/es active Active
-
2018
- 2018-12-15 SA SA521422474A patent/SA521422474B1/ar unknown
- 2018-12-15 SA SA518400666A patent/SA518400666B1/ar unknown
- 2018-12-17 PH PH12018550206A patent/PH12018550206A1/en unknown
- 2018-12-17 DO DO2018000287A patent/DOP2018000287A/es unknown
- 2018-12-17 CL CL2018003645A patent/CL2018003645A1/es unknown
- 2018-12-21 CO CONC2018/0014018A patent/CO2018014018A2/es unknown
-
2019
- 2019-01-04 EC ECSENADI2019185A patent/ECSP19000185A/es unknown
- 2019-08-30 US US16/557,180 patent/US10889574B2/en active Active
-
2020
- 2020-04-06 JP JP2020068458A patent/JP7352509B2/ja active Active
-
2021
- 2021-03-22 KR KR1020210036824A patent/KR102379584B1/ko active Active
- 2021-06-21 JP JP2021102648A patent/JP7669206B2/ja active Active
-
2023
- 2023-07-06 JP JP2023111632A patent/JP7773506B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19000185A (es) | Método para producir derivado de difenilmetano | |
| MX2021005598A (es) | Sintesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras. | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| MX2018014162A (es) | Procesos para preparar oligomeros de morfolino fosforodiamidato. | |
| MX376259B (es) | Produccion de 4-metil-tetrahidropiranos 2-sustituidos a partir de materiales de partida con contenido de 2-alquil-4,4-dimetil-1,3-dioxanos. | |
| CO2018013834A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| EA201500648A1 (ru) | (6r,10r)-6,10,14-триметилпентадекан-2-он, получаемый из 6,10-диметилундец-5-ен-2-она или 6,10-диметилундека-5,9-диен-2-она | |
| CR20170168A (es) | FIBRAS DE POLIPROPILENO MEJORADAS, MÉTODOS PARA PRODUCIRLAS Y SUS USOS PARA lA PRODUCCIÓN DE PRODUCTOS DE FIBROCEMENTO | |
| MX2017011407A (es) | Metodo para producir esteres de tetrahidropiranilo. | |
| GB2504245A (en) | Synthesis and use of glycoside derivatives of propofol | |
| CO2018013831A2 (es) | Procesos para preparar oligómeros de morfolino fosforodiamidato | |
| NZ720106A (en) | A process for the preparation of regadenoson | |
| MX2020009462A (es) | Procesos para la preparación de compuestos de pirimidinilciclopentano. | |
| CL2022001806A1 (es) | Método para producir derivado de difenilmetano. | |
| IN2013MU01219A (es) | ||
| AR102166A1 (es) | Método de fabricación de un péptido derivado de tapsigargina | |
| MX2016008281A (es) | Procedimientos mejorados para producir propilenglicol. | |
| ES2689371A8 (es) | Procedimiento para la preparación de pamoato de pirvinio y sus formas cristalinas | |
| BR112023000227A2 (pt) | Processo para preparação de dismina | |
| MX2022001845A (es) | Metodo para eliminar del vidrio metales perturbadores tales como hierro. | |
| BR112019008420A2 (pt) | processo para a preparação de 1-(4-clorofenil)pirazol-3-ol cristalino | |
| MX2014014512A (es) | Proceso para producir 4-ciclohexil-2-metil-2-butanol. | |
| EP2690084A4 (en) | METHOD FOR PRODUCING A HYDROXYL GROUP-CONTAINING ACETAL COMPOUND | |
| BR112018012696A2 (pt) | processo aperfeiçoado para fabricação de crotonilaminopiridinas | |
| BR112018010041A2 (pt) | processo para a síntese de intermediários úteis para a preparação de derivados de 1,3,4-triazina |